Core Insights - AngioDynamics is experiencing significant growth in its MedTech portfolio, particularly with the Auryon platform, which has generated over $60 million in revenue this year, up from zero at launch in September 2020 [1][4] - The company is transitioning from a legacy interventional radiology focus to a more science-driven MedTech portfolio, targeting larger and faster-growing markets [2][3] - CEO Jim Clemmer plans to retire later this year but will remain involved as a major shareholder and advisor during the leadership transition [4][17] Product and Market Developments - Auryon, a laser-based atherectomy platform, has seen nearly 20% growth year-to-date, with increased traction in hospitals and higher average selling prices [5] - The AlphaVac system, targeting pulmonary embolism, is positioned as a differentiated product in the VTE market, which is still early in its penetration curve, with only about 15% market penetration [6][7] - NanoKnife, used for treating intermediate-risk prostate cancer, has received an on-label indication and is expected to expand into benign prostatic hyperplasia (BPH) [8][9][16] Financial Performance and Projections - AngioDynamics is debt-free with positive adjusted EBITDA and expects to be cash-flow positive by fiscal 2026, with MedTech products projected to exceed 50% of revenue by fiscal 2027 [4][11][14] - The company's MedTech products have achieved a 25% compound annual growth rate over the past five years, with continued growth anticipated [10][11] - Management plans to optimize the portfolio further as MedTech becomes a larger share of the business, with no substantial M&A expected in the near term [13][14] Leadership Transition - The company will conduct a deliberate search for a new CEO, considering both internal and external candidates, with no rush to finalize the appointment [17][18] - Clemmer's retirement is based on personal circumstances, and he feels confident in the company's recent execution and results [17][18]

NeuroPace FY Conference Summary Company Overview - **Company**: NeuroPace (NasdaqGM: NPCE) - **Industry**: Medical Technology, specifically focused on epilepsy treatment through neurostimulation Key Highlights 1. **Mission Statement**: NeuroPace aims to transform the lives of people suffering from epilepsy by reducing or eliminating debilitating seizures, demonstrating a strong commitment to patients and clinicians [2][3] 2. **Strategic Positioning**: The company is well-positioned for growth with strong fundamentals, best-in-class technology, and a significant market opportunity in the neurostimulation space for drug-resistant epilepsy [3][4] 3. **Revenue Milestone**: NeuroPace achieved $100 million in revenue for the first time, marking a significant milestone with a 25% year-on-year growth for 2025 [5][6] 4. **Core Technology**: The RNS System is a unique cranial implant that continuously monitors and tailors therapy based on individual patient needs, leading to improved outcomes over time [4][11] 5. **Market Opportunity**: The total addressable market (TAM) for drug-resistant epilepsy is estimated to exceed $3 billion, with approximately 1.2 million patients in the U.S. suffering from drug-resistant epilepsy [5][11] Financial Performance 1. **2025 Results**: - Total revenue: $100 million - Core RNS revenue: $81.7 million, also reflecting a 25% growth [5][6] - Gross margins: 77.2% for the year [6] 2. **2026 Guidance**: Projected revenue of $98-$100 million with RNS revenue growth of $20-$22 million and gross margins between 81% and 82% [10][45] Growth Strategy 1. **Indication Expansion**: Plans to expand indications for idiopathic generalized epilepsy and pediatric patients, with a focus on leveraging real-world data for growth [9][10] 2. **Product Development**: Development of AI tools to enhance therapy effectiveness and efficiency, including remote programming capabilities and next-generation hardware [10][20] 3. **Market Development**: Expansion into community centers and Level 3 epilepsy centers to increase access to RNS therapy [35][36] Clinical Insights 1. **Patient Outcomes**: The RNS System has shown up to 82% median seizure reduction at three years, with best-in-class data supporting its efficacy [15][16] 2. **Unique Dataset**: NeuroPace has amassed over 24 million individualized EEG recordings, which will be utilized to develop AI algorithms for personalized therapy [17][18] Competitive Landscape 1. **Generalized Epilepsy Market**: There are currently no FDA-approved devices for drug-resistant idiopathic generalized epilepsy, presenting a significant opportunity for NeuroPace [41][42] 2. **Strategic Partnerships**: Collaborations with pharma and biotech companies to monitor biomarker responses in clinical trials, enhancing the value of the RNS device [43][44] Conclusion - NeuroPace is positioned for strong growth with a focus on expanding its market presence, enhancing its technology, and improving patient outcomes through innovative solutions in epilepsy treatment. The company is optimistic about its future, with a robust strategy in place for 2026 and beyond [49][50]

Market Opportunity & Prevalence - The prevalence-based market opportunity for Barostim is estimated at $10.5 billion in the U S HFrEF market[8, 9] - Heart failure affects nearly 6.7 million adults in the U S [10] - The company is less than 1% penetrated into its addressable market[36] Clinical Efficacy & Safety - Barostim implantation has a 97% freedom from major complications rate[54, 56] - Barostim shows a clinically relevant 94% response rate[58] - Real-world evidence demonstrates an 85% relative reduction in hospital visits per year post-Barostim implant (average 1 92 years) compared to pre-implant (12 months)[67, 68] Financial Performance & Guidance - Preliminary Q4 2025 worldwide revenue is $15 9–$16 1 million[104] - Preliminary 2025 worldwide revenue is $56 5–$56 7 million, with a gross margin of 84%-86%[104, 105] - The company expects total revenue between $63 0 million and $67 0 million for the full year of 2026[108] Growth Strategy - The company's strategy focuses on improving salesforce productivity, driving deep adoption in targeted centers, and addressing barriers to adoption[70, 71] - The company is focusing therapy awareness efforts on the clinicians and patients that surround targeted centers[84] - The company has received IDE approval for BENEFIT-HF, a potential landmark randomized controlled trial (RCT) in HF, with a trial size of 2,500 patients[94, 95]

This presentation and any documents incorporated by reference may contain market data that we obtain from industry sources. These sources do not guarantee the accuracy or completeness of the information. Although we believe that our industry sources are reliable, we do not independently verify the information. The market data may also include projections that are based on other projections. While we believe these assumptions and projections are reasonable and sound, as of the date hereof, actual results may ...

Financial Performance & Growth - Preliminary 2025 total revenue is expected to be approximately $100 million, representing a 25% year-over-year increase[12, 15, 18] - Core RNS System revenue grew by 25% in 2025, driven by sustained demand and increased utilization[12, 18] - Q4 2025 total revenue is estimated at $26.6 million, a 24% increase year-over-year[15] - Gross margin for 2025 is approximately 77.2%, an increase of 330 basis points year-over-year[15] - The company projects revenue between $98 million and $100 million for FY26, with RNS revenue growth of approximately 20-22% and gross margin around 81-82%[21] RNS System & Clinical Data - The RNS System has been used in over 8,000 patients[12] - The RNS System demonstrated a median seizure reduction of 75% at 9 years in the original FDA study results[35] - The RNS Post-Approval Study showed an 82% median seizure reduction at 3+ years[35, 37] - Preliminary NAUTILUS results showed an 18-month median seizure reduction of 77% in LGS patients[61] Market & Expansion - The annual target market opportunity is estimated at over $3.5 billion[12] - Approximately 1.2 million people in the U S have drug-resistant epilepsy (DRE)[25, 56] - The company is focused on expanding access to the RNS System in generalized epilepsy, pediatrics, and community channels[74]

Company Overview - CooperCompanies is a leading global medical device company with FY25 revenue of $41 billion[7] - The company's products are sold in more than 130 countries and it has over 15000 employees in 45+ countries[7] - CooperCompanies operates through two business units: CooperVision (CVI) and CooperSurgical (CSI)[7] Financial Performance and Guidance - CooperCompanies' total revenue has more than doubled in the last decade, with a CAGR of 86% from 2015 to 2025[9] - The company provides FY26 revenue guidance of $4299 - $4338 million, with organic growth of 45% - 55%[10] - CooperVision's FY26 revenue guidance is $2900 - $2925 million, with organic growth of 45% - 55%[10] - CooperSurgical's FY26 revenue guidance is $1399 - $1413 million, with organic growth of 4% - 5%[10] - Non-GAAP EPS guidance for FY26 is $445 - $460[10] - The company targets free cash flow of $575 - $625 million for FY26[10] Market Position and Strategy - CooperVision is the 1 contact lens company in the world in terms of wearers[22] - The global soft contact lens market is an $11 billion market growing at 4-5% annually[16, 18] - CooperSurgical is a leading fertility company in the medical device industry, addressing a ~$3 billion global market with 4-6% annual growth[34]

Company Overview - Establishment Labs is a medical technology company focused on breast aesthetics and reconstruction, emphasizing innovation to enhance women's health and well-being [2] - The company has been operational for 20 years, selling over 4.5 million devices across 90 countries [3] Recent Performance - Establishment Labs reported a 27% growth on a global basis for the year 2025, indicating strong market performance [3] - The company successfully launched its products in the U.S. after receiving FDA approval at the end of 2024, achieving a strong start in its first year [3] Future Outlook - Establishment Labs is well-positioned for significant growth in 2026 and beyond, with a focus on science-based innovation that sets a new standard in the breast aesthetics and reconstruction market [2][3]

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [4][5]. Stock Price Decline - On October 23, 2025, Integer revised its 2025 sales guidance down to between $1.840 billion and $1.854 billion, significantly below analysts' expectations. The company also projected a net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026. This announcement led to a stock price drop of $35.22 per share, or over 32%, from $109.11 to $73.89 [6].

Company Overview - The company is a global leader in the injectable medicine space, showcasing a strong competitive advantage through its proprietary solutions and reputation for quality, reliability, and scale [3]. Business Model and Growth - The company has an attractive business model that supports long-term organic growth of 7% to 9% and margin expansion, primarily driven by a shift in product mix [4]. - The underlying drivers of growth are centered around high-value product components [4].

PresentationGood morning. I'm David Adlington. I head up the research team for medtech for JPMorgan in London. It's my pleasure to introduce Britt Meelby Jensen, CEO of Ambu, and there'll be Q&A afterwards this. Britt, over to you.Britt JensenChief Executive Officer Thank you, David, and good morning, everyone. I've been looking forward to present at this year's JPMorgan conference. For those of you who remember last year, I was excited last year to present double-digit growth and strong progress on our ZOO ...